In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise
Adjusted analyses To account for baseline imbalances between treatment groups, multivariable regression analyses were performed (Table 3)
The products were marketed as research-grade, yet the website provided instructions for dissolving, mixing and self-injecting the powder
Overdose may cause severe nausea, vomiting, or low blood sugar
Don't forget lemon water its so simple but effective
It signals fullness to appetite centers in the brain and quiets the constant background pull toward food